NCT03810196View on ClinicalTrials.gov

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Acute LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromesAcute Lymphoblastic LeukemiaMixed Lineage LeukemiaLymphoblastic LymphomaBurkitt LymphomaJuvenile Myelomonocytic Leukemia
Interventions
DEVICE

CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback

Peripheral stem cell (PSC) product will be processed using the CliniMACS device for TCRαβ and T cell depletion. Approximately 10% of the PSCs will undergo CD45RA depletion and cryopreservation. Patients will receive CD45RA depleted infusion after the TCRab PSCT.

Trial Locations (1)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
lead

Children's Hospital of Philadelphia

OTHER